Sumitomo Chemical Company, Limited Q2 2025 Earnings Recap

Sumitomo Chemical’s Q2 fiscal 2025 results show notable improvements in core operating income and net profits, driven by strong sales at Sumitomo Pharma and favorable foreign exchange conditions.

Key Takeaways

• Core operating income surged to JPY 108.7 billion, up JPY 79.2 billion year-over-year, reflecting robust performance in Essential & Green Materials and Sumitomo Pharma.
• Net income attributable to owners of the parent reached JPY 39.7 billion, a substantial increase of JPY 46.2 billion compared to the prior year.
• Sales revenue fell to JPY 1,954 billion, down JPY 146 billion year-on-year, primarily impacted by decreased volumes across most segments.
• Strong performance in Sumitomo Pharma was underscored by sales gains from ORGOVYX and reduced selling expenses.
• The company improved its cash position, with equity rising to JPY 1,179.6 billion but experienced a drop in free cash flow to JPY 41 billion, reflecting increased working capital demands.